<DOC>
	<DOC>NCT02924402</DOC>
	<brief_summary>This study will determine a dose and schedule for XmAb13676 in the treatment of CD20 expressing hematologic malignancies.</brief_summary>
	<brief_title>Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Able to provide written informed consent Diagnosis of either NonCLL B cell malignancy or CLL/SLL Ineligible for or have exhausted standard therapeutic options Last dose of antiCD20 antibody therapy must have been &gt;4 weeks before study entry ECOG performance status 02 Not a candidate for or refusing treatment with hematopoietic stem cell transplantation Fertile patients must agree to use effective contraception during and for 4 weeks after completion of study Able and willing to complete the entire study Cytotoxic chemotherapy, radiotherapy, or immunotherapy within 4 weeks, or small molecule or investigational agents within 6 elimination halflives Prior allogeneic stem cell or solid organ transplantation Failure to recover from Grade 3 or 4 toxicity from previous treatment Multiple myeloma/plasma cell leukemia or B cell acute lymphoblastic leukemia Known intolerance to CD20 monoclonal antibody therapy History of primary central nervous system lymphoma or neoplastic central nervous system disease Platelet count &lt; 50 x 10^9/L Absolute neutrophil count &lt; 1.0 x 10^9/L Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at screening &gt; 3x upper limit of normal (ULN) Bilirubin &gt; 1.5 mg/dL Estimated creatinine clearance &lt; 50 mL/min Active/uncontrolled autoimmune disease Clinically significant cardiac/cardiovascular disease, or pulmonary compromise Seizure disorder History of stroke with the past year History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion Evidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entry Positive test for human immunodeficiency virus (HIV) or hepatitis C antibodies Positive test for HbsAg, or positive test for HBcAb (unless serology is positive due to recent intravenous immunoglobulin therapy) Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>B-cell Prolymphocytic Leukemia</keyword>
	<keyword>Transformed Lymphoma</keyword>
	<keyword>Burkitt's Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Hairy Cell Leukemia</keyword>
	<keyword>Splenic Marginal Zone Lymphoma</keyword>
	<keyword>Waldenstrom's Macroglobulinemia</keyword>
	<keyword>Variant Hairy Cell Leukemia</keyword>
	<keyword>Splenic B-cell Lymphoma/Leukemia</keyword>
	<keyword>Lymphoplasmacytic Lymphoma</keyword>
	<keyword>Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT)</keyword>
	<keyword>MALT Lymphoma</keyword>
	<keyword>Nodal Marginal Zone Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>In Situ Follicular Neoplasia</keyword>
	<keyword>Duodenal-type Follicular Lymphoma</keyword>
	<keyword>Large B-cell Lymphoma with IRF4 rearrangement</keyword>
	<keyword>Primary Cutaneous Follicle Center Lymphoma</keyword>
	<keyword>Diffuse Large B-cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>T-cell/Histiocyte-Rich Large B-cell Lymphoma</keyword>
	<keyword>Primary Cutaneous DLBCL, leg type</keyword>
	<keyword>EBV-positive DLBCL, NOS</keyword>
	<keyword>EBV-positive Mucocutaneous Ulcer</keyword>
	<keyword>DLBCL Associated with Chronic Inflammation</keyword>
	<keyword>Lymphomatoid Granulomatosis</keyword>
	<keyword>Primary Mediastinal (Thymic) Large B-cell Lymphoma</keyword>
	<keyword>Intravascular Large B-cell Lymphoma</keyword>
	<keyword>ALK+ Large B-cell Lymphoma</keyword>
	<keyword>Plasmablastic Lymphoma</keyword>
	<keyword>Primary Effusion Lymphoma</keyword>
	<keyword>HHV8+ DLBCL</keyword>
	<keyword>Burkitt-like Lymphoma with 11q Aberration</keyword>
	<keyword>High-grade B-cell Lymphoma</keyword>
	<keyword>B-cell Lymphoma, unclassifiable</keyword>
	<keyword>Post-transplant Lymphoproliferative Disorder</keyword>
	<keyword>PTLD</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>High-grade Lymphoma</keyword>
</DOC>